News

Lawsuits, multimillion-dollar losses, and a failed merger: Inside Adam Bierman's tumultuous reign as CEO of cannabis company MedMen

Business Insider · Jeremy Berke · last updated
Former MedMen CEO Adam Bierman felt like he, and the upstart cannabis company he led, was hitting its stride in the middle of 2018. Under his leadership, a near-billion-dollar merger with cannabis company Pharmacann blew up before the deal closed. Much like every other cannabis company, he had to turn to family-run businesses to raise money — particularly those with investments in other edgy, emerging industries like gambling or alcohol. In 2018, when Bierman was running the company, MedMen’s board was composed of seven outside directors, none of whom remain on the board today. He said he still thinks deeply about the future of the cannabis industry and what could have been with MedMen.
View full article

here today, more tomorrow

We’ve launched briefing.center with a focus on the press and media.

And we’ve added Citizen Cartwright, a daily quick-read news summary by veteran Washington journalist Linda Cartwright. We’ve also created a new voting rights knowledge center for Citizen Cartwright subscribers. (You can sign up for a dedicated morning email at citizencartwright.com.)

You can sign up here for full access to press and media and Citizen Cartwright on briefing.center.

You can use briefing.center as the center of your information management, or just one of your tools. We’re happy to discuss your information needs.

Sign up